Kenvue (KVUE) Beats Q1 Earnings and Revenue Estimates
Kenvue (KVUE) came out with quarterly earnings of $0.24 per share, beating the Zacks Consensus Estimate of $0.22 per share. This compares to earnings of $0.28 per share a year ago.
Listerine, Tylenol Maker Kenvue Tops Estimates, Lifts Sales Outlook
Shares of Kenvue (KVUE) rose in premarket trading Thursday after the maker of Band-Aid, Tylenol, and Listerine reported first-quarter results better than analysts' estimates.
Kenvue stock climbs as second quarter comes in ahead of forecasts
Consumer brands firm Kenvue Inc (NYSE:KVUE) traded on the front foot in Thursday's early deals, as its second quarter beat expectations (but, fell short in year-over-year comparatives). Net sales totalled $3.74 billion in Kenvue's first quarter, exceeding the consensus forecast of $3.68 billion whilst 3.9% lower than last year's digit.
Ahead of Kenvue (KVUE) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Beyond analysts' top -and-bottom-line estimates for Kenvue (KVUE), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2025.
2 Stocks Down 89% and 15% to Buy Right Now
A third of the year is now over, and the stock market has seen incredible levels of volatility across the stretch. The S&P 500 index is down roughly 9.5% from its high as of this writing, and the Nasdaq Composite index has fallen 13.5%.
Kenvue (KVUE) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Kenvue (KVUE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tariffs Could Keep the Federal Reserve on Hold: 5 High-Yield Dividend Kings Are Our Top Calls
High-yield dividend stocks are a favorite among investors for good reason.
Kenvue + Johnson & Johnson: I Choose To Own The Whole 'Humpty Dumpty'
Johnson & Johnson's spin-off of Kenvue has created two resilient defensive stocks in the healthcare sector, ideal for accumulation during market volatility. Despite being off their highs, both JNJ and Kenvue present attractive buying opportunities due to their low betas and relatively high dividends. These are exactly the resilient defensive stocks in an un-loved healthcare sector that investors are now piling into as the VIX spikes.
Faber Report: Kenvue settles proxy fight with activist Starboard
CNBC's David Faber breaks down the latest news on Kenvue.
Kenvue settles proxy fight with activist Starboard, appoints three directors
Consumer health company Kenvue said on Wednesday it had appointed three new directors to its board as part of an agreement with activist investor Starboard Value.
Kenvue settles proxy fight with activist Starboard
CNBC's David Faber joins 'Squawk Box' to report on the latest news.
Kenvue settles proxy fight with activist Starboard, sources tell CNBC
Kenvue settles proxy fight with activist Starboard, sources tell CNBC
